Thymosin Alpha 1 — Competitive Intelligence Brief

Thymosin Alpha 1 (Thymosin Alpha 1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Immunology.

marketed Immunomodulator T-cell maturation pathway / thymic differentiation Immunology Small molecule

Target snapshot

Thymosin Alpha 1 (Thymosin Alpha 1) — Xuanwu Hospital, Beijing. Thymosin Alpha 1 is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic differentiation and activation of immune cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Thymosin Alpha 1 TARGET	Thymosin Alpha 1	Xuanwu Hospital, Beijing	marketed	Immunomodulator	T-cell maturation pathway / thymic differentiation
PF-06863135 + lenalidomide	pf-06863135-lenalidomide	Pfizer	marketed	small molecule + immunomodulatory drug	unknown
β-1,3/1,6-D-glucan	β-1,3/1,6-D-glucan	Al-Azhar University	marketed	Immunomodulator; biological response modifier	Dectin-1 (β-glucan receptor); Complement receptor 3 (CR3)
CMP 001	cmp-001	Pfizer Inc.	marketed	Immunomodulatory Agent	TLR9
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
Ixazomib plus low-dose lenalidomide	Ixazomib plus low-dose lenalidomide	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Proteasome inhibitor and immunomodulatory agent	Proteasome and cereblon
Peg-IFN + WB RBV for 24 weeks	Peg-IFN + WB RBV for 24 weeks	National Taiwan University Hospital	marketed	Immunomodulator + nucleoside analog antiviral combination	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

1. Actavis Mid-Atlantic LLC · 1 drug in this class
2. Active Biotech AB · 1 drug in this class
3. Air Force Military Medical University, China · 1 drug in this class
4. Astellas Pharma Inc · 1 drug in this class
5. Bayer · 1 drug in this class
6. Beijing Children's Hospital · 1 drug in this class
7. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
8. Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
9. Chang Gung Memorial Hospital · 1 drug in this class
10. ALK-Abelló A/S · 1 drug in this class